HARVARD MEDICAL SCHOOL
Advancing cancer vaccine design using deep learning to predict peptide-HLA class I binding and immunogenicity
Advancing cancer vaccine design using deep learning to predict peptide-HLA class I binding and immunogenicity is a funding opportunity from HARVARD MEDICAL SCHOOL, up to 43056, closing April 30, 2030.
Apr 30, 2030
(1369d left)Overview
Project Summary Melanoma is an aggressive form of skin cancer with high inter- and intratumor heterogeneity. Despite advances in immune checkpoint inhibitor therapies, patients fail to achieve long-term remission. Cancer vaccines offer a promising, personalized approach by targeting neoantigens, tumor-specific…